March 28, 2024 Jeff Trigilio Dear Jeff:Cullinan Therapeutics, Inc. • May 15th, 2024 • Biological products, (no disgnostic substances)
The purpose of this Separation and Transition letter agreement (this “Agreement”) is to confirm the terms of your separation from Cullinan Oncology, Inc. (the “Company”) and your post-separation consulting arrangement with the Company. Capitalized terms not defined herein shall have the respective meanings ascribed to them in the Employment Agreement between you and the Company dated January 7, 2021 (the “Employment Agreement”).
